$CAMP

Young Richard A purchased $27K of CAMP

Young Richard A purchased 16,378 shares of Camp4 Therapeutics Corp (CAMP) at $1.65 on 2026-08-03.

Original reporting
SEC EDGAR · Young Richard A
Published Aug 5, 2026, 9:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 9:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CAMP
Bullish
medium confidence
Mentioned
$CAMP
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CAMPBullishLow
01

Why it matters

The only new fact is the director’s open-market purchase details (shares, price, total value, and post-transaction holdings). No operational updates, guidance, or regulatory/clinical catalysts are included.

02

Market read

Traders may note the insider buy as a small sentiment input, but it does not introduce new fundamental information.

03

What to watch

The filing does not state motivations, and there is no 10b5-1 plan involvement; without additional context, the signal may be weak.

Relevance 4/10Novelty 3/10Timing: Form 4 filed Aug. 5, covering an Aug. 3 purchase.

Background

This is an SEC Form 4 insider transaction disclosure for Camp4 Therapeutics, reported by a director.

Company-level read

Ticker impact

$CAMPBullishMedium confidence
Context

Director Young Richard bought 16,378 shares of Camp4 Therapeutics at $1.65/share for about $27.0K, disclosed via Form 4 filed Aug. 5.

Expected impact

Near-term impact likely limited; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 insider buys can influence short-term sentiment, but the transaction size ($27K) is small relative to typical market-moving thresholds and provides no new operating or guidance information.

Market effects

No clear sector read-through from a single small insider purchase.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine liquidity or diversification activity and do not necessarily imply improved near-term prospects.

Key entities

  • Camp4 Therapeutics Corp

    Subject of the Form 4 insider transaction disclosure.

  • Young Richard

    Director who reported the open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CAMPMedAI 8/10

CAMP4 Q2 Net Loss Widens; On Track To Advance CMP-002 Into Phase 1/2 Trial In Q4 2026

CAMP4 Therapeutics (CAMP) reported Q2 2026 net loss of $33.5M, or $0.58/share, versus $12.6M, or $0.62/share, a year earlier. The wider loss was mainly due to a $20.9M non-cash derivative fair value change. R&D rose to $10.8M. CAMP4 received Australia and Argentina clearance for a Phase 1/2 CMP-002 trial, expected to start in Q4 2026, and raised $50.1M, extending runway to end-2028.

$CAMPMed

Camp4 Therapeutics Corp (CAMP): Results of Operations and Financial Condition

Camp4 Therapeutics Corp (CAMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth qua